Group 1 - The company, Huaxia Eye Hospital Group Co., Ltd., has announced that it will not distribute cash dividends, issue bonus shares, or increase capital reserves during the reporting period [2][3] - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period [4] - The company completed the distribution of cash dividends amounting to RMB 183,143,875.20 on July 14, 2025, with a distribution of RMB 2.20 per 10 shares [4]

Meeting Overview - The third board meeting of Huaxia Eye Hospital Group Co., Ltd. was held on August 21, 2025, combining both in-person and remote attendance [1] - All 7 board members attended the meeting, with one member represented by proxy due to personal reasons [1] - The meeting was chaired by Mr. Chen Fengguo, and it complied with relevant regulations [1] Resolutions Passed - All resolutions were passed unanimously with 7 votes in favor, 0 against, and 0 abstentions [2][3][4] - The resolutions included the approval of the semi-annual report and the special report on the management and use of raised funds [2][4] - A proposal to amend the company's articles of association was approved, which will eliminate the supervisory board, transferring its powers to the audit committee of the board [2][4] Future Actions - Several resolutions are pending submission to the shareholders' meeting for further approval [2][3][4] - The company will publish detailed information regarding the resolutions on its official website [5]

| 2025 | | 华厦眼科医院集团股份有限公司 | 年半年度报告摘要 | | | --- | --- | --- | --- | --- | | 证券代码：301267 | | 证券简称：华厦眼科 | 公告编号：2025-025 | | | 华厦眼科医院集团股份有限公司 | | | | | | 华厦眼科医院集团股份有限公司 | | | | 2025 年半年度报 | | 告摘要 | | | | | | 一、重要提示 | | | | | | 本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 | | | | | | 资者应当到证监 | | | | | | 会指定媒体仔细阅读半年度报告全文。 | | | | | | 除下列董事外，其他董事亲自出席了审议本次半年报的董事会会议 | | | | | | 未亲自出席董事姓名 | | 未亲自出席董事职务 | 未亲自出席会议原 | | | 因 | | 被委托人姓名 | | | | 苏庆灿 | | 董事长 | 因个人原 | | | 因 | | 陈凤国 | | | | 非标准审计意见提示 | | | | | | □适用 | ?不适用 | ...

Meeting Overview - The third supervisory board meeting of Huaxia Eye Hospital Group Co., Ltd. was held on August 21, 2025, combining both in-person and remote attendance [1] - All three supervisors attended the meeting, which was chaired by Ms. Huang Niya, and complied with relevant regulations [1] Resolutions Passed - The supervisory board unanimously approved the written confirmation of the 2025 semi-annual report, ensuring its authenticity and completeness, with a voting result of 3 in favor, 0 against, and 0 abstentions [1] - The supervisory board confirmed that the report on the management and use of raised funds for the first half of 2025 accurately reflects the company's situation and complies with legal requirements, with the same voting result [2] - The board agreed to extend the implementation period for certain fundraising projects, stating that this does not change the amount of funds or the direction of investment, nor does it materially affect the company's financial status or shareholder interests, with a voting result of 3 in favor, 0 against, and 0 abstentions [2][3]

证券代码：301267 证券简称：华厦眼科 公告编号：2025-029 华厦眼科医院集团股份有限公司 关于召开 2025 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 华厦眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 8 月 21 日召开了第三届董事会第十次会议，决定于 2025 年 9 月 10 日（星期三）召开公 司 2025 年第一次临时股东会，本次股东会采用现场表决与网络投票相结合的方 式召开，现将本次会议的有关事项通知如下： 一、召开会议的基本情况 于提请召开 2025 年第一次临时股东会的议案》，本次股东会会议的召开符合有 关法律、行政法规、部门规章、规范性文件、业务规则和《公司章程》等相关规 定。 （1）现场会议时间：2025 年 9 月 10 日（星期三）下午 15:00； 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 9 月 10 日 9:15-9:25、9:30-11:30 和 13:00-15:00； 公司将通过深圳证券交易所交易系统和互联网投票系统 （http://wltp ...

中国国际金融股份有限公司 关于华厦眼科医院集团股份有限公司 部分募集资金投资项目延长实施期限的核查意见 中国国际金融股份有限公司（以下简称"中金公司"、"保荐机构"）作为华厦眼科医 院集团股份有限公司（以下简称"华厦眼科"或"公司"）首次公开发行股票并在创业板上 市及持续督导的保荐机构，根据《证券发行上市保荐业务管理办法》《上市公司募集资 金监管规则》 《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》等相关法律、法规和规范性文件的规定， 对华厦眼科部分募集资金投资项目延长实施期限的事项进行了审慎核查，具体情况如下： 一、募集资金投资项目的基本情况 经中国证券监督管理委员会《关于同意华厦眼科医院集团股份有限公司首次公开发 行股票注册的批复》 （证监许可〔2022〕2085 号）同意，公司首次公开发行人民币普通 股（A 股）6,000.00 万股，每股发行价为人民币 50.88 元，募集资金总额为人民币 净额为人民币 276,849.25 万元。上述募集资金已于 2022 年 10 月 28 日到账，容诚会计 师事务所（特殊普通合伙）对募集资金到位 ...

Core Points - The "Brilliant Vision" charity event in Tibet aims to promote technical exchanges in ophthalmology between Beijing and Tibet, enhancing the transfer of high-quality medical resources to the region by 2025 [1][2] - The event is led by Wei Wenbin, Vice President of Beijing Tongren Hospital, and involves a volunteer medical team providing assistance in four hospitals across three regions in Tibet [1][2] Medical Assistance - The charity event completed 60 cataract surgeries and 20 complex vitreoretinal surgeries, marking the first complex artificial lens suspension surgery in the region [2] - Health consultations and large-scale health outreach activities were conducted, benefiting the local population, along with training for local ophthalmologists [2][5] - The expert team identified a high incidence of retinal vascular occlusion due to hypertension and hyperlipidemia, emphasizing the need for better management of chronic eye diseases in the region [5][8] Training and Technology - The event included training sessions for local ophthalmologists on technical standards and practical laser operations, addressing the unique challenges of healthcare in remote areas [2][8] - Wei Wenbin suggested utilizing AI to enhance diagnostic capabilities and facilitate remote consultations, allowing national experts to support the region [8]

Group 1 - The core viewpoint of the article is that Huaxia Eye Hospital (301267) reported its semi-annual financial results, showing growth in both revenue and net profit [1] - The company achieved a revenue of 2.139 billion yuan in the first half of the year, representing a year-on-year increase of 4.31% [1] - The net profit attributable to shareholders was 282 million yuan, reflecting a year-on-year growth of 6.2% [1]

Core Insights - Huaxia Eye Hospital (301267) reported its semi-annual results for 2025, showing a revenue of 2.139 billion yuan, representing a year-on-year growth of 4.31% [1] - The net profit attributable to shareholders reached 282 million yuan, with a year-on-year increase of 6.2% [1] - Basic earnings per share were reported at 0.34 yuan [1]

格隆汇8月24日丨华厦眼科(301267.SZ)公布2025年半年度报告，报告期实现营业收入21.39亿元，同比增 长4.31%；归属于上市公司股东的净利润2.82亿元，同比增长6.20%；归属于上市公司股东的扣除非经常 性损益的净利润2.78亿元，同比增长2.43%；基本每股收益0.34元。 ...